Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Colorcon
Moodys
Harvard Business School
Express Scripts

Last Updated: February 7, 2023

Details for Patent: 8,404,724


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,404,724 protect, and when does it expire?

Patent 8,404,724 protects BEVYXXA and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 8,404,724
Title:Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Abstract: Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.
Inventor(s): Sinha; Uma (San Francisco, CA), Hollenbach; Stanley J. (South San Francisco, CA), Abe; Keith (South San Francisco, CA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:11/999,957
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 8,404,724

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y INHIBITING COAGULATION See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y INHIBITING COAGULATION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,404,724

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007333377 See Plans and Pricing
Canada 2671502 See Plans and Pricing
Canada 2913963 See Plans and Pricing
China 101652136 See Plans and Pricing
China 105193799 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Johnson and Johnson
Mallinckrodt
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.